Stevanato Group (STVN) Competitors

Stevanato Group logo
€15.56 -0.24 (-1.52%)
Closing price 03:59 PM Eastern
Extended Trading
€15.73 +0.17 (+1.12%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

STVN vs. ICLR, RGEN, TECH, AVTR, and BIO

Should you buy Stevanato Group stock or one of its competitors? Stevanato Group's main competitors and comparable companies include Icon (ICLR), Repligen (RGEN), Bio-Techne (TECH), Avantor (AVTR), and Bio-Rad Laboratories (BIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Stevanato Group compare to Icon?

Icon (NASDAQ:ICLR) and Stevanato Group (NYSE:STVN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Icon presently has a consensus price target of $213.76, suggesting a potential upside of 9.82%. Given Icon's higher possible upside, equities analysts clearly believe Icon is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icon
1 Sell rating(s)
9 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.50
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67

Stevanato Group has a net margin of 11.24% compared to Icon's net margin of 5.45%. Stevanato Group's return on equity of 10.51% beat Icon's return on equity.

Company Net Margins Return on Equity Return on Assets
Icon5.45% 7.73% 4.39%
Stevanato Group 11.24%10.51%6.22%

In the previous week, Stevanato Group had 10 more articles in the media than Icon. MarketBeat recorded 13 mentions for Stevanato Group and 3 mentions for Icon. Stevanato Group's average media sentiment score of 1.34 beat Icon's score of 0.65 indicating that Stevanato Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Icon
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Icon has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

Icon has higher revenue and earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Icon$8.23B1.81$229.34M$5.8133.50
Stevanato Group€1.34B3.56€158.21M€0.5827.19

95.6% of Icon shares are held by institutional investors. 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Icon beats Stevanato Group on 9 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Repligen?

Stevanato Group (NYSE:STVN) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

97.6% of Repligen shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Stevanato Group has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group€1.34B3.56€158.21M€0.5827.19
Repligen$738.26M14.53$48.89M-$0.21N/A

In the previous week, Stevanato Group had 9 more articles in the media than Repligen. MarketBeat recorded 13 mentions for Stevanato Group and 4 mentions for Repligen. Stevanato Group's average media sentiment score of 1.34 beat Repligen's score of 1.00 indicating that Stevanato Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Repligen
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Stevanato Group has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Repligen has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Repligen has a consensus target price of $178.57, indicating a potential upside of 6.43%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67
Repligen
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.83

Stevanato Group has a net margin of 11.24% compared to Repligen's net margin of -1.47%. Stevanato Group's return on equity of 10.51% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group11.24% 10.51% 6.22%
Repligen -1.47%5.49%3.93%

Summary

Stevanato Group beats Repligen on 9 of the 16 factors compared between the two stocks.

How does Stevanato Group compare to Bio-Techne?

Stevanato Group (NYSE:STVN) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Stevanato Group has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Bio-Techne has a consensus target price of $68.92, indicating a potential downside of 5.33%. Given Bio-Techne's higher possible upside, analysts plainly believe Bio-Techne is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67
Bio-Techne
1 Sell rating(s)
14 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.12

99.0% of Bio-Techne shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bio-Techne has lower revenue, but higher earnings than Stevanato Group. Stevanato Group is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group€1.34B3.56€158.21M€0.5827.19
Bio-Techne$1.22B9.41$181.86M$1.0966.79

Bio-Techne has a net margin of 13.95% compared to Stevanato Group's net margin of 11.24%. Bio-Techne's return on equity of 13.00% beat Stevanato Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group11.24% 10.51% 6.22%
Bio-Techne 13.95%13.00%10.57%

In the previous week, Stevanato Group had 6 more articles in the media than Bio-Techne. MarketBeat recorded 13 mentions for Stevanato Group and 7 mentions for Bio-Techne. Stevanato Group's average media sentiment score of 1.34 beat Bio-Techne's score of 1.14 indicating that Stevanato Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bio-Techne
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Bio-Techne beats Stevanato Group on 11 of the 17 factors compared between the two stocks.

How does Stevanato Group compare to Avantor?

Stevanato Group (NYSE:STVN) and Avantor (NYSE:AVTR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

95.1% of Avantor shares are owned by institutional investors. 0.3% of Avantor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Stevanato Group had 8 more articles in the media than Avantor. MarketBeat recorded 13 mentions for Stevanato Group and 5 mentions for Avantor. Stevanato Group's average media sentiment score of 1.34 beat Avantor's score of 0.42 indicating that Stevanato Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Avantor
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Stevanato Group has higher earnings, but lower revenue than Avantor. Stevanato Group is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stevanato Group€1.34B3.56€158.21M€0.5827.19
Avantor$6.55B1.61-$530.20M$0.5031.09

Avantor has a consensus price target of $14.77, indicating a potential downside of 5.01%. Given Avantor's higher possible upside, analysts clearly believe Avantor is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67
Avantor
1 Sell rating(s)
13 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.06

Stevanato Group has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Avantor has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Stevanato Group has a net margin of 11.24% compared to Avantor's net margin of 5.08%. Stevanato Group's return on equity of 10.51% beat Avantor's return on equity.

Company Net Margins Return on Equity Return on Assets
Stevanato Group11.24% 10.51% 6.22%
Avantor 5.08%9.79%4.74%

Summary

Stevanato Group beats Avantor on 10 of the 16 factors compared between the two stocks.

How does Stevanato Group compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has a net margin of 39.45% compared to Stevanato Group's net margin of 11.24%. Stevanato Group's return on equity of 10.51% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories39.45% 3.58% 2.51%
Stevanato Group 11.24%10.51%6.22%

Bio-Rad Laboratories currently has a consensus target price of $366.67, suggesting a potential upside of 0.02%. Given Bio-Rad Laboratories' higher possible upside, equities research analysts plainly believe Bio-Rad Laboratories is more favorable than Stevanato Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Stevanato Group
0 Sell rating(s)
5 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.67

In the previous week, Stevanato Group had 1 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 13 mentions for Stevanato Group and 12 mentions for Bio-Rad Laboratories. Stevanato Group's average media sentiment score of 1.34 beat Bio-Rad Laboratories' score of 0.10 indicating that Stevanato Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Stevanato Group
7 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

Bio-Rad Laboratories has higher revenue and earnings than Stevanato Group. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.82$759.90M$37.979.65
Stevanato Group€1.34B3.56€158.21M€0.5827.19

Summary

Bio-Rad Laboratories beats Stevanato Group on 9 of the 17 factors compared between the two stocks.

Get Stevanato Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for STVN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STVN vs. The Competition

MetricStevanato GroupLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap€4.71B€10.84B€7.83B€23.17B
Dividend YieldN/A1.45%2.47%3.79%
P/E Ratio26.8351.5434.3429.41
Price / Sales3.517.098.003.27
Price / Cash16.2826.7921.0215.64
Price / Book2.575.814.764.04
Net Income€158.21M€57.47B€3.52B€1.07B
7 Day Performance13.78%-5.43%-5.34%-3.09%
1 Month Performance-17.82%-0.98%-3.61%-1.21%
1 Year Performance-29.33%18.47%0.01%5.63%

Stevanato Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STVN
Stevanato Group
3.7657 of 5 stars
€15.56
-1.5%
N/A-28.4%€4.71B€1.34B26.836,010
ICLR
Icon
3.94 of 5 stars
$209.80
+2.5%
$213.76
+1.9%
+20.0%$16.05B$8.23B36.0840,100
RGEN
Repligen
2.9288 of 5 stars
$179.52
+3.5%
$178.57
-0.5%
+10.1%$11.45B$805.61MN/A2,000
TECH
Bio-Techne
2.1614 of 5 stars
$72.86
+0.1%
$68.92
-5.4%
+22.6%$11.44B$1.22B63.353,000
AVTR
Avantor
2.4358 of 5 stars
$15.91
+2.8%
$14.77
-7.2%
+36.7%$10.77B$6.55B31.7913,500

Related Companies and Tools


This page (NYSE:STVN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners